FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says

The FDA's decision to allow Regenxbio to refile its gene therapy application marks a significant step forward for rare disease treatments, potentially accelerating access to innovative therapies. This development highlights the evolving regulatory landscape that can impact the pace of medical advancements in the biotech industry. For consumers, it offers hope for new options in managing previously untreatable conditions.

• Regenxbio can now refile its gene therapy application without placebo requirements.
• The FDA's flexibility may streamline approval processes for rare disease drugs.
• This case signals a potential shift towards more adaptive regulatory approaches in biotech.